Planned 18,733-share sale by Pharvaris (PHVS) chief medical officer
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Lu Peng, Chief Medical Officer of Pharvaris N.V., reported an exercise-and-sale sequence under a Rule 10b5-1 trading plan. Peng exercised options to acquire 18,733 shares of common stock at $2.59 per share and sold the same number of shares in open-market transactions at weighted average prices around $30 on April 29–30, 2026.
Following these transactions, Peng directly holds 66,083 shares of Pharvaris common stock and 219,474 stock options from the referenced grant, which remains outstanding until February 3, 2030.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 18,733 shares ($565,859)
Net Sell
6 txns
Insider
Lu Peng
Role
Chief Medical Officer
Sold
18,733 shs ($566K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | -- |
| Exercise | Common Stock | 15,000 | $2.59 | $39K |
| Sale | Common Stock | 15,000 | $30.2418 | $454K |
| Exercise | Stock Option (Right to Buy) | 3,733 | $0.00 | -- |
| Exercise | Common Stock | 3,733 | $2.59 | $10K |
| Sale | Common Stock | 3,733 | $30.0649 | $112K |
Holdings After Transaction:
Stock Option (Right to Buy) — 219,474 shares (Direct, null);
Common Stock — 81,083 shares (Direct, null)
Footnotes (1)
- This is a scheduled exercise and sale from 10b5-1 trading plan. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.00 to $30.20. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.75 to $30.2418. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter. The number of derivative securities beneficially owned following the reported transaction has been updated to correct an error in the number of options remaining from this grant as previously reported. This correction does not reflect a new transaction.
Key Figures
Shares sold: 18,733 shares
Exercise price: $2.59 per share
Weighted average sale price 4/29: $30.0649 per share
+4 more
7 metrics
Shares sold
18,733 shares
Total common shares sold in open-market trades on April 29–30, 2026
Exercise price
$2.59 per share
Strike price for options exercised for 18,733 common shares
Weighted average sale price 4/29
$30.0649 per share
Common stock sales on April 29, 2026; prices ranged $30.00–$30.20
Weighted average sale price 4/30
$30.2418 per share
Common stock sales on April 30, 2026; prices ranged $30.75–$30.2418
Shares owned after trades
66,083 shares
Common shares directly owned by Lu Peng following transactions
Options remaining
219,474 options
Derivative securities beneficially owned after transactions from referenced grant
Option expiration
February 3, 2030
Expiration date of the stock option grant exercised in part
Key Terms
Rule 10b5-1 trading plan, weighted average sale price, Stock Option (Right to Buy), restricted stock units, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"reported date pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The reported price represents a weighted average sale price"
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
restricted stock units financial
"shares of common stock acquired upon vesting of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
derivative securities beneficially owned financial
"The number of derivative securities beneficially owned following the reported transaction"
FAQ
What insider transactions did Pharvaris (PHVS) CMO Lu Peng report?
Lu Peng reported exercising options for 18,733 Pharvaris shares at $2.59 and selling 18,733 common shares in open-market trades around $30. The transactions occurred on April 29–30, 2026, as part of a pre-arranged Rule 10b5-1 trading plan.
What is the strike price and expiration of Lu Peng’s exercised Pharvaris (PHVS) options?
The options exercised to acquire 18,733 Pharvaris shares had a strike price of $2.59 per share and an expiration date of February 3, 2030. Footnotes note 25% vested on February 3, 2021, with remaining shares vesting in equal monthly installments thereafter.